利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.039 秒)

    Human antibodies that bind human 17-A1/EpCAM tumor antigen
    24.
    发明授权
    Human antibodies that bind human 17-A1/EpCAM tumor antigen 失效
    结合人17-A1 / EpCAM肿瘤抗原的人抗体

    公开(公告)号：US07227002B1

    公开(公告)日：2007-06-05

    申请号：US09403107

    申请日：1998-04-14

    申请人： Peter Kufer ,  Tobias Raum

    发明人： Peter Kufer ,  Tobias Raum

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  C12P21/04 ,  C07H21/04

    CPC分类号： C07K16/00 ,  A61K38/00 ,  C07K16/30 ,  C07K2317/34

    摘要： The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.

    摘要翻译： 本发明提供在人体中低或不是免疫原性的抗人抗体或其片段。 特别地，抗体或片段针对人肿瘤抗原，优选针对人肿瘤抗原17-1A，也称为EpCAM，EGP或GA 733-2。 还提供了包含上述抗体或其片段的药物组合物。

    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY
    25.
    发明申请
    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开
    跨物种特异性单链单链单链抗体

    公开(公告)号：US20110275787A1

    公开(公告)日：2011-11-10

    申请号：US13122280

    申请日：2009-10-01

    申请人： Peter Kufer ,  Tobias Raum

    发明人： Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/18 ,  C07K14/435

    CPC分类号： C07K16/2863 ,  C07K16/2803 ,  C07K16/2878 ,  C07K16/2884 ,  C07K2317/31 ,  C07K2317/34

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

    摘要翻译： 本发明涉及双特异性单链抗体分子，其包含由能够结合人和非黑猩猩灵长类CD3ε链的表位的一个抗体可变结构域组成的第一结合结构域，其中所述表位是氨基酸序列的一部分 包括在由SEQ ID NOs组成的组中。 2,4,6和8以及能够结合人和非黑猩猩灵长类动物靶标抗原的表位的第二结合结构域。 本发明还涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3抗原表位的第一结合结构域; （ε）链，其中所述表位是包含在SEQ ID NO中的氨基酸序列的一部分。 2,4,6和8以及由能够与人的表位结合的一个抗体可变结构域和非黑猩猩灵长类动物靶标抗原组成的第二结合结构域。 本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。 本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

    Method of identifying binding site domains that retain the capacity of binding to an epitope
    26.
    发明授权
    Method of identifying binding site domains that retain the capacity of binding to an epitope 有权
    鉴定保留与表位结合的能力的结合位点结构域的方法

    公开(公告)号：US07435549B1

    公开(公告)日：2008-10-14

    申请号：US09554465

    申请日：1998-11-16

    申请人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    发明人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    IPC分类号： G01N33/53

    CPC分类号： C40B40/02 ,  A61K38/00 ,  C07K14/70525 ,  C07K14/70528 ,  C07K14/70532 ,  C07K16/3046 ,  C07K2319/00 ,  C12N15/1037

    摘要： The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further relates to a kit comprising components such as panels of recombinant vectors of bacterial libraries transfected with a panel of recombinant vectors which is useful in carrying out the method of the invention. Furthermore, binding site domains and fusion proteins obtainable by the method of the invention as well as antibody-like molecules comprising such domains and proteins are described. Furthermore, pharmaceutical and diagnostic compositions containing the above-described fusion proteins and polypeptides are provided.

    摘要翻译： 本发明涉及一种鉴定结合位点结构域的方法，当定位在重组双或多价多肽中的至少另一个结构域的C-末端时，其保留与表位结合的能力。 本发明还涉及一种试剂盒，其包含诸如用于实施本发明的方法的重组载体的一组重组载体转染的细菌文库的重组载体的片段的组分。 此外，描述了可通过本发明的方法获得的结合位点结构域和融合蛋白以及包含这种结构域和蛋白质的抗体样分子。 此外，提供含有上述融合蛋白和多肽的药物和诊断组合物。

    DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
    27.
    发明申请
    DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY 审中-公开
    用于管理EpCAMxCD3双相抗体的剂量

    公开(公告)号：US20120244161A1

    公开(公告)日：2012-09-27

    申请号：US13496836

    申请日：2010-09-20

    申请人： Gerhard Zugmeier ,  Peter Kufer ,  Dominik Ruttinger ,  Sabine Kaubitzsch

    发明人： Gerhard Zugmeier ,  Peter Kufer ,  Dominik Ruttinger ,  Sabine Kaubitzsch

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/2809 ,  A61K39/39541 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  A61K2300/00

    摘要： The present invention relates to a method (dosage regimen) for administering an EpCAMxCD3 bispecific antibody to a human patient, comprising (a) administering continually a first dose of said antibody for a first period of time; and consecutively (b) administering continually a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating EpCAM positive epithelial cancer cells in a human patient, or for ameliorating and/or preventing a medical condition mediated by the continued administration of an EpCAMxCD3 bispecific antibody to a human patient. The present invention also relates to the use of an EpCAMxCD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose and the second dose as defined in the methods/dosage regimen of the present invention is disclosed as well.

    摘要翻译： 本发明涉及向人类患者施用EpCAMxCD3双特异性抗体的方法（剂量方案），其包括（a）连续给予第一剂量的所述抗体一段时间; 并连续地（b）连续施用第二剂量的所述抗体第二时间段，其中所述第二剂量超过所述第一剂量。 本发明的方法（以及本发明的给药方案）也适用于治疗人类患者中的EpCAM阳性上皮癌细胞，或用于改善和/或预防由继续施用EpCAMxCD3双特异性抗体介导的医学病症 给一个人的病人。 本发明还涉及EpCAMxCD3双特异性抗体在制备用于如前述权利要求中任一项所述的方法中使用的药物组合物中的用途。 还公开了包含本发明的方法/剂量方案中定义的第一剂量和第二剂量的药物包装或试剂盒。

    Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
    28.
    发明授权
    Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders 有权
    包含用于治疗b细胞相关疾病的双特异性抗cd3抗CD19抗体构建体的药物组合物

    公开(公告)号：US07635472B2

    公开(公告)日：2009-12-22

    申请号：US10554852

    申请日：2004-05-26

    申请人： Peter Kufer ,  Ralf Lutterbuse ,  Birgit Kohleisen ,  Steven Zeman ,  Patrick Bauerle

    发明人： Peter Kufer ,  Ralf Lutterbuse ,  Birgit Kohleisen ,  Steven Zeman ,  Patrick Bauerle

    IPC分类号： A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622

    摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.

    摘要翻译： 本发明涉及包含双特异性单链抗体构建体的药物组合物，其包含对人CD3和人CD19特异性的结合结构域，其中相应的可变重链区（VH）和相应的可变轻链区（VL）区域被布置， VH（CD19）-VL（CD19）-VH（CD3）-VL（CD3）或VH（CD3）-VL-（CD3）-VH（CD19）-VL（从N末端至C末端） CD19）。 还公开了用于制备针对人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的药物组合物和医用/药物用途的方法。

    DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY
    29.
    发明申请
    DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY 有权
    用于管理CD19XCD3双相抗体的剂量计

    公开(公告)号：US20120328618A1

    公开(公告)日：2012-12-27

    申请号：US13504665

    申请日：2010-10-27

    申请人： Dirk Nagorsen ,  Peter Kufer ,  Gerbach Zugmaier ,  Patrick Baeuerle

    发明人： Dirk Nagorsen ,  Peter Kufer ,  Gerbach Zugmaier ,  Patrick Baeuerle

    IPC分类号： A61K39/395 ,  A61P35/02 ,  A61P35/00

    CPC分类号： C07K16/2809 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/55 ,  C07K16/2803 ,  C07K2317/31 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/5094 ,  G01N2800/52

    摘要： The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19×CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well.

    摘要翻译： 本发明涉及用于评估（分析）通过向所述患者施用CD19×CD3双特异性抗体介导的人类患者的潜在不良反应的风险的方法，包括确定所述患者的B细胞与T细胞的比率， 其中约1:5或更低的比率指示对所述患者具有潜在不利影响的风险。 因此，本发明涉及用于向B：T细胞比例为约1:5或更低的人类患者施用CD19×CD3双特异性抗体的方法（剂量方案），其包括（a）施用第一剂量的所述抗体 第一段时间; 并且连续地（b）在第二时间段内施用第二剂量的所述抗体，其中所述第二剂量超过所述第一剂量。在一些实施方案中，所述抗体的第三剂量施用第三时间段。 该给药方案可以用于治疗恶性CD19阳性淋巴细胞的方法或用于改善和/或预防由所述双特异性抗体施用介导的不良作用。 本发明还涉及CD19×CD3双特异性抗体用于制备用于本发明方法的药物组合物的用途。 还公开了包含本发明的方法/剂量方案中定义的第一剂量和第二剂量以及任选地第三剂量的所述抗体的药物包装或试剂盒。

    Means and methods for the treatment of tumorous diseases
    30.
    发明授权
    Means and methods for the treatment of tumorous diseases 有权
    治疗肿瘤疾病的手段和方法

    公开(公告)号：US08007796B2

    公开(公告)日：2011-08-30

    申请号：US12095951

    申请日：2006-11-29

    申请人： Patrick Baeuerle ,  Peter Kufer ,  Matthias Klinger ,  Eugen Leo

    发明人： Patrick Baeuerle ,  Peter Kufer ,  Matthias Klinger ,  Eugen Leo

    IPC分类号： A61K39/00 ,  A61K39/935

    CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/31

    摘要： The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.

    摘要翻译： 本发明涉及用于预防，治疗或改善无痛或侵袭性B细胞非霍奇金淋巴瘤（B NHL）和B细胞白血病的药物方法和方法，其包括向受试者施用双特异性单链抗体构建体，以及使用 用于制备用于预防，治疗或改善无痛或侵袭性B细胞非霍奇金淋巴瘤（B NHL）和B细胞白血病的药物组合物的双特异性单链抗体构建体。 该构建体以规定的日剂量施用至少1周。 此外，本发明涉及包含根据本发明使用的双特异性单链抗体构建体的试剂盒。